Pediatric acute myeloid leukemia

Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)

(2011) U. Creutzig et al.   BLOOD

Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study

(2011) E. A. Coenen et al.   BLOOD

Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

(2011) N. Hijiya et al.   BLOOD

Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial

(2011) Brenda E. S. Gibson et al.   BRITISH JOURNAL OF HAEMATOLOGY

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia

(2011) Todd M. Cooper et al.   CANCER

Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia

(2011) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia

(2010) D. Niewerth et al.   BLOOD

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

(2010) C. Bachas et al.   BLOOD

Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses

(2010) Ursula Creutzig et al.   BRITISH JOURNAL OF HAEMATOLOGY

Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia

(2010) I. H. I. M. Hollink et al.   HAEMATOLOGICA

Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate

(2010) Jonas Abrahamsson et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657

(2010) Bianca F. Goemans et al.   LEUKEMIA RESEARCH

Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO-AML study

(2010) Lene Molgaard-Hansen et al.   PEDIATRIC BLOOD & CANCER

Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia

(2009) I. H. I. M. Hollink et al.   BLOOD

Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study

(2009) B. V. Balgobind et al.   BLOOD

Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study

(2009) Christian M. Zwaan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference

(2009) Franco Locatelli et al.   CLINICAL IMMUNOLOGY

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

(2009) Sima Jeha et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk-Stratified Therapy and the Intensive Use of Cytarabine Improves the Outcome in Childhood Acute Myeloid Leukemia: The AML99 Trial From the Japanese Childhood AML Cooperative Study Group

(2009) Ichiro Tsukimoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Disease Risk on Efficacy of Matched Related Bone Marrow Transplantation for Pediatric Acute Myeloid Leukemia: The Children's Oncology Group

(2008) John T. Horan et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

(2008) I H I M Hollink et al.   LEUKEMIA